Tags : Central Precocious Puberty

Tolmar’s Fensolvi Received the US FDA’s Approval to Treat Pediatric

Shots: The approval is based on P-III study which involves assessing of leuprolide acetate (LA,45 mg) in 64 children with central (gonadotropin-dependent) precocious puberty evaluating its safety and pharmacokinetics The study achieved its 1E i.e. 87% of children achieved a serum luteinizing hormone concentration of <4 IU/L at six months post injection with most common […]Read More